论文部分内容阅读
目的探索口咽鳞癌患者中p16蛋白状态以及EGFR表达对放疗近期和远期疗效的影响。方法回顾性分析首程治疗为本中心放疗且留存有放疗前肿瘤病理标本的39例口咽鳞癌患者,将患者按照p16蛋白状态和EGFR表达进行分组,比较放疗近期疗效以及总生存情况。结果 39例口咽鳞癌患者以Ⅳ期为主(84.6%),其中23例患者(59.0%)p16蛋白表达阳性。p16(+)者放疗后可以获得更好的肿瘤退缩,而EGFR的表达不同未发现与肿瘤退缩情况相关,多因素分析显示p16蛋白是影响总生存的独立预后因素。结论 p16蛋白阳性的口咽癌患者较阴性者放疗敏感性更高、预后更好,但需要扩大样本量进行验证。
Objective To investigate the effect of p16 protein status and EGFR expression on the short-term and long-term effects of radiation in patients with oropharyngeal squamous cell carcinoma. Methods Thirty-nine patients with oropharyngeal squamous cell carcinoma who underwent primary radiotherapy and had pre-radiotherapy tumor histology were retrospectively analyzed. The patients were divided into groups according to the expression of p16 protein and EGFR, and the short-term curative effect and overall survival were compared. Results The 39 cases of oropharyngeal squamous cell carcinoma were mainly stage Ⅳ (84.6%), of which 23 cases (59.0%) had positive p16 protein expression. p16 (+) after radiotherapy can get better tumor regression, and the expression of EGFR was not found associated with tumor regression, multivariate analysis showed that p16 protein is an independent prognostic factor affecting the overall survival. Conclusion Patients with p16 protein-positive oropharyngeal cancer have higher sensitivity and better prognosis than patients with negative or negative response, but need to expand the sample size for verification.